MUC16/CA125 is not the only HIO factor capable of binding IgG-type antibodies [12], therefore broad in vitro screening of ADC antibody components may be warranted against a panel of HIO-positive and -negative cancer lines to identify those that are most effective for antigen binding, internalization and target cell killing. Here, MUC16 is linked to cancer.